香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因 依賴該等內容而引致的任何損失承擔任何責任。 於本公司招股章程根據香港法例第32章公司（清盤及雜項條文）條例送呈香港 公司註冊處處長登記之前，不會向香港公眾人士提出要約或邀請。倘於適當時 候向香港公眾人士提出要約或邀請，有意投資者務請僅依據本公司與香港公 司註冊處處長登記的招股章程作出投資決定，招股章程的文本將於要約期內 向公眾人士提供。 Guangzhou Novaken Pharm Co., Ltd. – 1 – (a) 在聯交所網站登載本公告，並不引致本公司、其獨家保薦人、整體協調人、 顧問或包銷銀團成員在香港或任何其他司法管轄區必須進行發售或配售 的責任。本公司最終會否進行發售或配售仍屬未知之數； (b) 本公告所涉及的上市申請尚未獲批准，聯交所及證監會或會接納、發回或 拒絕有關的公開發售及╱或上市申請； (c) 本公告不應被視為誘使認購或購買任何證券，亦不擬構成該等勸誘； (d) 本公司或其任何聯屬人士、其顧問或包銷銀團成員概無於任何司法管 ...

Core Conclusions - The report highlights a significant market event where the Shanghai Composite Index surged by 1.38% on the first trading day of 2026, breaking the 4000-point threshold, indicating a strong market sentiment and increased trading volume across A-shares [1] Group 1: Market Signals - Signal One: Transition from "Volume Hesitation" to "Volume Initiation" suggests that the substantial increase in trading volume at the start of the year alleviates concerns about previous low-volume gains. The report anticipates a "re-inflation bull market" driven by the Federal Reserve's interest rate cuts and the appreciation of the RMB, leading to a significant increase in A-share trading volume, with expected lows of 500 billion and 1 trillion in total A-share turnover in September 2024 and June 2025 respectively, confirming the initiation of a major upward trend [1][6] - Signal Two: The report notes a structural thematic and growth market emerging, referred to as the "spring excitement" market, with various themes gaining traction such as brain-machine interfaces, robotics, and commercial aerospace. However, it cautions that sustained high trading volumes may not be realistic, and a potential reduction in volume could lead to a narrowing of thematic trading focus [2] - Signal Three: The insurance sector is identified as a new leader in the bull market, with its recent volume increase confirming the market's upward trend. Historically, insurance has been a key driver in market rallies, and the report suggests a shift from intermediary institutions to asset management institutions as the market transitions from a volatile to a more stable investment environment [3][12] Group 2: Industry Allocation - The report emphasizes the importance of focusing on the insurance sector and a "new high" combination for industry allocation. It suggests that 2025 may be a prelude to a bull market, with 2026 expected to witness the main trend. Key sectors to watch include non-ferrous metals, new consumption (food and beverage/travel), and high-end manufacturing (power equipment/chemicals/healthcare) [4][14]

Group 1 - WuXi AppTec's third, fourth, and sixth largest shareholders reduced their holdings by 2% from November 20, 2025, to January 5, 2026, totaling 59.6751 million shares at prices ranging from 84.66 to 95.08 CNY per share [1] Group 2 - Robotech's subsidiary ficonTEC signed a significant contract worth approximately 770,000 euros (about 63.0784 million CNY) with a Swiss client, representing over 5.70% of the company's audited revenue for 2024 [2] Group 3 - Times New Material signed a sales contract for wind turbine blades worth approximately 3.32 billion CNY, effective from October 1, 2025, to December 31, 2025, which is expected to positively impact the company's performance [3] Group 4 - YHLO signed a strategic cooperation framework agreement with Brain Machine Star Chain to enhance market expansion and sales of brain-machine interface products, leveraging both companies' resources [4] Group 5 - Guanshang Technology plans to acquire 100% of Liao Jing Electronics through a combination of stock issuance and cash payment, with the deal expected to create synergies in the defense technology sector [5] Group 6 - Siwei Control announced the termination of its control change planning due to a lack of agreement on core terms, with no significant adverse impact on its business operations [6] - Baihua Pharmaceutical also terminated its control change planning for similar reasons, with no major negative effects on its operations [8] Group 7 - Chaoying Electronics adjusted the investment amount for its AI high-end printed circuit board expansion project from 1.468 billion CNY to 3.315 billion CNY, with a new production capacity target of 166,500 square meters annually [9] Group 8 - Baotailong's controlling shareholder was ordered to rectify its failure to fulfill a share buyback commitment, having only bought back 10.0018 million shares out of a planned 20 to 40 million shares [10]

Core Viewpoint - The article discusses the evolution of "bull stocks" in the A-share market over the past five years, highlighting changes in industry focus, market capitalization preferences, and performance metrics. Group 1: Yearly Analysis of Bull Stocks - In 2021, the new energy sector was a fertile ground for bull stocks, with midstream manufacturing and materials contributing 29% and 24% respectively. The market began shifting from large caps to "small high-tech" stocks, with 21 stocks entering the top 100 despite being in the bottom 20% by market cap at the start of the year [2] - In 2022, consumer services, machinery, and electric equipment sectors produced the most bull stocks. A notable trend was the preference for smaller companies, with 83 bull stocks having a market cap below 10 billion yuan at the beginning of the year. The median profit growth of these stocks was 157.99%, significantly higher than the overall A-share growth of 1.38% [3] - In 2023, the TMT sector contributed 50% of the bull stocks, with midstream manufacturing and essential consumption following. The trend towards smaller market caps continued, with only 4 stocks in the top 20% by market cap at the start of the year. The profitability of bull stocks was lower than the overall A-share market, indicating a shift in investor focus towards high elasticity and thematic opportunities [5] - In 2024, the TMT sector remained dominant, accounting for 37% of bull stocks. The number of stocks in the top 20% by market cap increased to 21, showing a shift from the previous year's small-cap focus. Profitability slightly improved compared to the overall market, with a median growth rate of 13.62% compared to 2.05% for A-shares [6] - In 2025, midstream manufacturing contributed 35% of bull stocks, with TMT at 27%. The trend of smaller market caps persisted, with over half of the bull stocks starting the year in the top 60% by market cap [8] Group 2: Market Trends and Preferences - The analysis reveals a significant shift in market preferences over the past five years, moving from a focus on large-cap stocks to a greater appreciation for mid and small-cap stocks. This reflects changing investor sentiment and market dynamics [8] - The profitability and growth metrics of bull stocks have fluctuated, with a notable increase in the emphasis on earnings growth over return on equity (ROE) in recent years. This indicates a broader market trend towards valuing high growth potential [2][3][5][6] - The article concludes that the search for bull stocks should adapt to changing market conditions, suggesting that relying on previous years' templates may not yield successful outcomes in the future [8]

Core Viewpoint - The article highlights the significant reforms and innovations undertaken by Fangchenggang City, focusing on practical measures that address the urgent needs of the community and businesses, leading to high-quality development and improved public satisfaction. Group 1: Reform Initiatives - Fangchenggang City has launched 117 "small but beautiful" micro-reform initiatives since 2025, covering various sectors to benefit the public, enterprises, and grassroots [3] - The medical insurance department has reduced the approval time for outpatient chronic disease treatment qualifications from 18 working days to as fast as 1 working day, benefiting over 1,300 insured patients [3] - The forestry department has established an online and offline dual-channel for logging permits, reducing the average processing time from 10 working days to 1 working day, improving efficiency by 90% [3] Group 2: Economic Development - The city has achieved a significant increase in industrial output, with the industrial output value of the Dongxing Industrial Park nearly doubling since its establishment, and the total foreign trade import and export volume reaching 25.938 billion yuan, showing a notable year-on-year growth [5] - The smart factory output accounts for 77.5% of the total industrial output, with the establishment of the first national aluminum oxide industry model and the first intelligent detection line for steel in the region [5] - The cross-border e-commerce comprehensive pilot zone has been approved, with expected exports exceeding 12 billion yuan [5] Group 3: Service Innovation - Fangchenggang City has implemented a "project steward" model to provide full-cycle support for projects, ensuring that projects can start immediately after land acquisition [7] - The customs has introduced a "1+1+N" smart inspection model, reducing the inspection time for imported mineral products by over 50%, saving enterprises more than 100 million yuan annually [8] - The city has established a mechanism for enterprise demands and departmental responses, resulting in a significant increase in new registered business entities, with a growth rate of 8.68% compared to the end of 2023, the highest in the region [8] Group 4: Healthcare and Industry - The establishment of a service system consisting of a service station and two centers has facilitated the rapid development of the medical device industry, increasing the number of production enterprises from 3 to 40 [6] - The nuclear power company has achieved 100% localization of nuclear power equipment, with an installed capacity exceeding 9.4 million kilowatts, enhancing the resilience and strength of the regional industrial chain [6] Group 5: Overall Impact - The reforms in Fangchenggang City have led to a GDP growth of 7% in the first three quarters of 2025, leading the region, with 23 indicators showing growth rates at the forefront of the region [8] - The city has transformed its reform approach from "government-led" to "enterprise-driven," fostering a collaborative environment for development [9] - The practical reforms have significantly improved service efficiency and public satisfaction, demonstrating the effectiveness of the city's reform strategies [9]

Core Insights - The pharmaceutical industry is undergoing a transformation driven by policy collaboration, technological breakthroughs, and industrial restructuring, with a clear shift from price competition to value creation [1] - Shenzhen Haiwang Bioengineering Co., Ltd. is leveraging the new management team's arrival to implement asset optimization, focus on core businesses, and enhance innovation and research, marking a transition from scale expansion to quality and efficiency improvement [1] Industry Policy - The new national medical insurance drug list and the first commercial insurance innovative drug list took effect on January 1, 2026, creating a multi-tiered insurance system that opens diverse payment channels for innovative drugs [1] - The national centralized procurement has entered a new phase aimed at stabilizing clinical practices, ensuring quality, preventing collusion, and countering internal competition, guiding companies towards R&D innovation and quality enhancement [1] Management and Asset Optimization - The new management team established a strategic agenda focused on increasing sales gross margin, ensuring asset safety, improving financing channels, and optimizing capital returns, injecting strong momentum into the transformation [2] - The company is actively divesting non-core assets to enhance the operational quality and profitability of subsidiaries while reallocating limited funds to high-value areas to improve overall profitability [2] Business Focus and Innovation - Haiwang Bio is concentrating on three core sectors: pharmaceutical distribution, pharmaceutical manufacturing, and pharmaceutical R&D, driving business collaboration upgrades [3] - The pharmaceutical distribution sector showed strong performance, with medical device agency revenue reaching 4.986 billion yuan in the first half of 2025, establishing solid partnerships with industry leaders [3] - The pharmaceutical manufacturing sector has a gross margin of 36.14%, with strategies to promote production and sales collaboration [3] - R&D investment reached 31.68 million yuan in the first three quarters of 2025, with ongoing clinical trials for innovative drugs and expansion into traditional Chinese medicine and specialized food sectors [3] Governance Upgrade - The company has revised internal management systems to enhance governance transparency and decision-making efficiency, strengthening internal controls and shareholder return systems [3] - The management team has committed to focusing on high-efficiency business development over the next three years, particularly in the medical device and pharmaceutical manufacturing sectors [3] Industry Outlook - Industry experts note that Haiwang Bio's deep transformation aligns with the demands for high-quality development, showcasing determination and strength through asset optimization, business focus, innovation, and governance upgrades [4] - With the dual drivers of policy benefits and strategic focus, Haiwang Bio is expected to transition from a traditional pharmaceutical company to a technology-driven healthcare service provider, reconstructing its competitive edge [4]

Group 1 - The core viewpoint of the article highlights the strong performance of the CSI 500 ETF and broad-based indices, with a focus on the potential for a "healthy bull market" in the A-share market by 2025, driven by sectors such as TMT, new energy, and machinery [1] - The CSI 500 index, tracked by the CSI 500 ETF, consists of 500 small and mid-cap stocks, reflecting the overall performance of small-cap companies in the A-share market, with a balanced industry distribution including pharmaceuticals, electronics, and new energy [1] - The report indicates that mid-cap stocks are gaining strength, with significant contributions from the machinery, chemicals, and electronics sectors, and highlights that the communication sector shows a median net profit growth rate of 187.21% among the top 100 stocks [1]

Group 1 - The core viewpoint of the article highlights the active performance of the Hong Kong technology sector, with notable gains in stocks such as SenseTime-W, JD Health, and others, indicating a positive market sentiment [1] - The macroeconomic context includes the Federal Reserve's decision to lower interest rates as indicated in the December 2025 meeting minutes, alongside a rise in China's composite PMI output index to 50.7%, reflecting an expansion in production activities [1][13] - The net inflow of southbound funds exceeded 18.7 billion HKD on the first trading day of the year, while foreign capital showed a decreasing trend in outflows, with passive foreign capital inflows into Hong Kong and Chinese concept stocks reaching 900 million USD [1][13] Group 2 - GF Securities notes that the recent rise in Hong Kong stocks is supported by fundamentals, with signs of structural recovery in profitability expected to strengthen from the second half of 2024 due to stabilizing domestic and external demand [1][16] - The article mentions that the Hong Kong technology index consists of 30 leading tech companies selected based on high market capitalization, R&D investment, and revenue growth, with a flexible sample adjustment mechanism to maintain competitiveness [4] - The top five constituents of the Hong Kong technology index include Tencent Holdings, Alibaba-W, and Xiaomi Group, with significant weightings of 15.46%, 14.54%, and 13.50% respectively, indicating a high concentration in the index [9][7]

Group 1 - The PMI index has returned to the expansion zone, which is favorable for the spring market trend. The manufacturing PMI for December is reported at 50.1%, up from the previous value of 49.2%. This marks the first return to the expansion zone in nine months, indicating a marginal improvement in the economic fundamentals [1] - On Monday, both stock markets opened high and continued to rise, with trading volume increasing significantly. The Shanghai Composite Index closed near its daily high, marking the twelfth consecutive bullish day. The Shenzhen Component Index outperformed, surpassing the high from early October last year. Total trading volume exceeded 2.5 trillion yuan, a substantial increase from the previous trading day [1] - Market hotspots were primarily concentrated in the TMT (Technology, Media, and Telecommunications) and pharmaceutical sectors, with a leading performance from the technology sector. The Shanghai Composite Index has formed a small double bottom pattern and is currently challenging previous high points [1]

Core Viewpoint - The A-share market started 2026 on a positive note, with all three major indices rising, indicating a shift from valuation recovery in 2025 to profit-driven growth in 2026 [1][5][12] Market Performance - On January 5, 2026, the Shanghai Composite Index rose by 1.38% to 4023.42 points, the Shenzhen Component increased by 2.24% to 13828.63 points, and the ChiNext Index saw a rise of nearly 2.9% to 3294.55 points [5] - The total trading volume reached 2.57 trillion yuan, an increase of over 500 billion yuan compared to the previous trading day, with nearly 4200 stocks rising [6] Key Drivers - The "opening red" of the A-share market was attributed to multiple positive factors, including improved market sentiment, expectations of long-term capital inflows, and strong anticipation of further macroeconomic growth policies [6][12] - The technology sector, particularly AI, semiconductor, and brain-computer interface stocks, showed strong performance, contributing significantly to the index's rise [7][8] Sector Highlights - The brain-computer interface sector experienced a surge, with stocks like Beiyikang and Sanbo Brain Science hitting the daily limit, driven by news of overseas company Neuralink's plans for large-scale production [10][11] - Other sectors such as AI applications, medical devices, and insurance also performed well, with respective index increases of 9.95%, 6.83%, and 6.72% [8] Investment Opportunities - Institutions are focusing on technology growth, advanced manufacturing, and cyclical consumption for investment opportunities in 2026 [2][14] - A balanced investment strategy is recommended, emphasizing high-quality stocks alongside high-potential sectors such as non-bank financials, humanoid robots, and AI hardware [14][15] - The pharmaceutical sector is expected to present structural opportunities, particularly in innovative drugs and AI integration in healthcare [15]